Kodiak’s ongoing and planned clinical studies have a high probability of success to support a tarcocimab BLA in 2026 and a potential KSI-501 BLA in 2027 while supporting complementary and potentially differentiated commercial profiles Indication Phase 3 Study Primary Endpoint 6-Month Durability Results / Progress Tarcocimab RVO BEACON • Doubled treatment interval (Q8W) at PE (month 6) and ~50% of tarcocimab treated patients on 6-month dosing at Year 1 DR GLOW1 • 100% of patients on 6-month dosing at Year 1 Wet AMD DAYLIGHT Not Applicable • Monthly study of tarcocimab demonstrated favorable safety and non-inferior efficacy at Year 1 DR GLOW2 Superiority • Topline data on track for 1Q 2026 • Design mirrors successful GLOW1 study Wet AMD DAYBREAK Non- Inferiority • Expecting to close screening end of August • Topline data expected mid 2026 KSI-501 Wet AMD DAYBREAK Non- Inferiority Not Applicable • Expecting to close screening end of August • Topline data expected mid 2026 Wet AMD 2nd Pivotal TBD TBD • In planning • Exploring start in 4Q 2025 / 1Q 2026 • Targeting BLA mid-2027 Completed Ongoing Ongoing Planned 29